Android app on Google Play

Roth Capital Doubles PT on Keryx (KERX); Sees Another 200% Upside

January 28, 2013 11:27 AM EST Send to a Friend
Get Alerts KERX Hot Sheet
Price: $13.79 --0%

Rating Summary:
    11 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 9 | New: 6
Trade KERX Now!
Join SI Premium – FREE
Roth Capital's Joseph Pantginis boosted his price target on Keryx Biopharmaceuticals (NASDAQ: KERX) from $7 to $15 following his morning's positive Phase 3 data for Zerenex.

With shares of KERX up 46% mid-day to $5.01, the new price target represents another 200% upside.

For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst PT Change, Momentum Movers

Related Entities

Roth Capital

Add Your Comment